Andrew M. Brunner, MD - FLT3 Inhibitors in Action: Clinical Case Challenges in Newly Diagnosed AML

Please visit answersincme.com/860/CME-25-198904-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease and family medicine discuss complex immunization needs of all patients, especially those with altered immunocompetence. Upon completion of this activity, participants should be better able to: Review how having altered immunocompetence affects response to vaccines; Apply the national guideline recommendations for immunization in individuals with altered immunocompetence; and Formulate effective communication strategies to enhance vaccine uptake in individuals with altered immunocompetence.

Please visit answersincme.com/MPD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in myelodysplastic syndromes discusses strategies for the management of FLT3-mutated acute myeloid leukemia. Upon completion of this activity, participants should be better able to: Summarize guideline recommendations for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML); Recognize the clinical significance of the evidence for approved FLT3 inhibitors in the first-line treatment of newly diagnosed, FLT3-mutated AML; Formulate strategies to maximize the impact of FLT3 inhibitors in the management of patients with newly-diagnosed, FLT3-mutated AML.

Please visit answersincme.com/VYT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses the management of vasomotor symptoms (VMS) associated with menopause. Upon completion of this activity, participants should be better able to: Identify VMS as a consequence of menopause; Evaluate the efficacy and safety of new and emerging neurokinin (NK)-targeted therapies for VMS; Implement shared decision-making for optimal VMS treatment outcomes

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.

Please visit answersincme.com/AVD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, three experts in diabetes discuss approved and emerging once-weekly insulin analogs. Upon completion of this activity, participants should be better able to: Identify patients with T2D who may benefit from basal insulin therapy, including those suited for once-weekly formulations; Assess the clinical data of approved and emerging once-weekly basal insulin analogs; Evaluate opportunities and challenges associated with once-weekly basal insulin therapy.

Please visit answersincme.com/UDT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses primary chemoimmunotherapy regimens in advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Apply biomarker testing results to guide initial treatment decisions in advanced endometrial cancer; Select the optimal therapy for a given patient with endometrial cancer, based on the latest evidence; Design patient-centered, multidisciplinary care plans that support treatment continuity and patient survivorship.

Please visit answersincme.com/WTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hepatology and endocrinology discuss the impact of obesity on liver disease progression, current and emerging GLP-1 receptor agonist therapies, and strategies to optimize clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Upon completion of this activity, participants should be better able to: Identify how obesity impacts metabolic dysfunction–associated steatohepatitis (MASH) progression and liver health; Review current and emerging glucagon-like peptide-1 (GLP-1) receptor agonist (RA)–based therapies for the treatment of MASH; and Outline approaches to optimize patient outcomes in obesity-related liver disease.

Please visit answersincme.com/860/MED-ONC-03349-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts discuss how the latest data for first-line immunotherapy-based regimens informs personalized approaches for advanced NSCLC and how to elevate care through patient advocate–centered approaches. Upon completion of this activity, participants should be better able to: Differentiate the clinical profiles of NCCN-preferred first-line immunotherapy-based regimens for advanced NSCLC based on the latest data for disease with no actionable mutations and PD-L1 expression 50% or greater; Identify how first-line treatment selection varies for different patient subpopulations with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater; and Apply patient-centered strategies to optimize the integration of immunotherapy-based regimens into first-line treatment plans of patients with advanced NSCLC with no actionable mutations and PD-L1 expression 50% or greater.

Please visit answersincme.com/860/MED-RESP-03359-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, ENT and allergy experts present strategies for incorporating the latest biologic therapies for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) via case-based challenges. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Select appropriate biologic therapies for patients with CRSwNP based on patient-, disease-, and drug-related factors; Apply guideline recommendations for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP.

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.